Overview
Vladimir Torchilin has published more than 450 original papers, more than 200 reviews and book chapters, wrote and edited 15 books, and holds more than 40 patents. Google Scholar shows more than 90,000 citations of his papers with H-index of 132. He is Editor-in-Chief of Current Drug Discovery Technologies, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He has multiple national and international honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010. In 2021 Elsevier/Stanford analysis ranked him as a single highest-cited researcher among more than 130,000 ranked researches in the area of Pharmacology/Pharmacy. He is also selected by Clarivat as the 2023 Citaion Laureat. In 2005-2006 he served as a President of the Controlled Release Society. He also served as a mentor for more than 50 PhD students.
Specializations
- Nanomedicine
- Pharmaceutical Biotechnology
- Drug Delivery and Targeting
- Liposomes
Courses Taught
Advanced Physical Pharmacy (PMST 6250)
Advanced Drug Delivery Systems (PMST 6254)
Pharmacokinetics and Biopharmaceutics (PHSC 3430)
Awards
2023 Citation Laureat by Clarivate
2017 Outstanding Excellence Award from Pharmaceutica 2017, London, UK
2013 Blaise Pascal Medal in Biomedicine from the European Academy of Sciences
2013 Journal of Drug Targeting Life Achievement Award
2012 Alec Bangham Life Achievement Award
2010 Fellow, Controlled Release Society
2010 Founders Award, Controlled Release Society
2009 International Journal of Nanomedicine Distinguished Scientist Award
2007 Research Achievement Award from the Pharmaceutical Sciences World Congress
2005 Research Achievement Award in Pharmaceutics and Drug Delivery Award from the AAPS
2003 Fellow, American Association of Pharmaceutical Sciences (AAPS)
2002 Member, European Academy of Science
2002 Fellow, American Institute of Medical and Biological Engineering
1982 Lenin Prize of the USSR in Science and Technology
Grants
Source: NIH R01
Title: Nanocarriers for intracellular targeting
2008-2013
Source: NIH R01
Title: Layer-by-layer technology for poorly soluble drugs
2010-2014
Source: NIH
Title: Center for Cancer Nanotechnology Excellence
2010-2015
Source: NIH R01
Title: Lipid-dendrimer conjugates for siRNA and drug delivery
2015-2022
Source: NIH R01
Title: Mechanical Drugs
2016-2021
Publications
Filipczak N, Li X, Saawant GR, Yalamarty SSK, Luther E, Torchilin VP. Antibody-modified DNase I micelles specifically recognize the neutrophil extracellular traps (NETs) and promote their degradation. J Control Release. 2023;354:109-119.
Mendes LP, Rostamizadeh K, Gollomp K, Myerson JW, Marcos-Contreras OA, Zamora M, Luther E, Brenner JS, Filipczak N, Li X, Torchilin VP, Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps. MAbs. 2020; 12(1):1850394
Salzano G, Costa DF, Sarisozen C, Luther E, Mattheolabakis G, Dhargalkar PP, Torchilin VP. Mixed nanosized polymeric micelles as promoter of doxorubicin and miRNA-34a co-delivery triggered by dual stimuli in tumor tissue. Small, 2016;12:4837-4848.
F.Perche, S.Biswas, T.Wang, L.Zhu, V.P.Torchilin, Hypoxia-targeted siRNA delivery, Angew Chemie, 2014; 53:3363-3366.
Lukianova-Hleb EY, Ren X, Sawant RR, Wu X, Torchilin VP. Lapotko DO, On demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles, Nat Med, 2014; 20:78-84.
Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, Torchilin VP, Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer, Cancer Lett, 2014;343:224-231.
Zhu L, Wang T, Perche F, Taigind A, Torchilin VP. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety, Proc Natl Acad Sci USA, 2013; 100:17047-17052.
Torchilin VP, Recent advances with liposomes as pharmaceutical carriers, Nature Rev Drug Discov 2005; 4:145-160.
Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D’Souza GGM, Cell transfection in vitro and in vivo with non-toxic TAT peptide-liposome-DNA complexes, Proc Natl Acad Sci USA 2003; 100:1972-1977.
Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B, Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs, Proc Natl Acad Sci USA 2003; 100:6039-6044.
Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents, Trends Immunol 2001; 22:424-427.
